Elicio Therapeutics Secures $20 Million in Private Placement for Cancer Treatment Research
BOSTON, Aug. 12, 2024 - Elicio Therapeutics, a leading biotechnology company focused on developing innovative immunotherapies for cancer treatment, announced today the successful completion of a private placement for a 3.0% Senior Secured Convertible Promissory Note. The company raised an impressive $20.0 million through this transaction, which will be used to advance its pipeline of novel therapies.
The agreement, entered into on August 12, 2024, involved the issuance of the Convertible Note in accordance with the exemption from registration provided by the Securities Act of 1933, as amended. The purchaser of the Convertible Note was GKCC, LLC, an entity controlled by a member of Elicions Board of Directors.
This private placement represents a significant milestone for Elicio Therapeutics, positioning the company for continued growth and expansion in the cancer treatment market. With cancer being one of the leading causes of death worldwide, Elicions focus on developing innovative immunotherapies holds great promise for patients seeking effective and personalized treatment options.
Notable is Elicions exceptional BOSTON, Aug. 12, 2024 - Elicio Therapeutics, a leading biotechnology company focused on developing innovative immunotherapies for cancer treatment, announced today the successful completion of a private placement for a 3.0% Senior Secured Convertible Promissory Note. The company raised an impressive $20.0 million through this transaction, which will be used to advance its pipeline of novel therapies. "https://csimarket.com/stocks/at_glance.php?code=ELTX">ELTX&Le">Leverage Ratio performance, which reached a new company high of 4.03. Over the past twelve months, the company has demonstrated its commitment to financial soundness, with a Leverage Ratio of 1.26, driven by a repayment of liabilities totaling 24.33% during the trailing twelve months that concluded in the first quarter of 2024.
The successful private placement and improved Leverage Ratio affirm Elicio Therapeutics as a leader in the biotechnology sector. Investors can look forward to significant strides in cancer treatment research as the company deploys this new capital to accelerate the development of its pipeline of novel immunotherapies.
Comments